Evasc Neurovascular Announces Enrollment of First Patient in the French eCLIPs™ Safety, Feasibility and Efficacy Study (EESIS-FR)
13.1.2022 09:05:00 EET | Business Wire | Press release
Evasc Neurovascular, a pioneer in the development of disruptive endovascular treatments for cerebral aneurysms, announced today the enrollment of the first patient in its French eCLIPs™ Safety, Feasibility and Efficacy Study (EESIS-FR). The study will be conducted in France with the objective to evaluate the technical feasibility, safety, and efficacy of the eCLIPs products for the treatment of bifurcation aneurysms. The eCLIPs device has been granted ‘innovative’ status in the French Forfait Innovation program and the study is partially funded by the French National Authority for Health (HAS) within this program. Up to 28 neuro-interventional sites in France will enroll patients in this study.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220111006183/en/
Announcing the enrollment of the first patient in Evasc Neurovascular's French eCLIPs™ Safety, Feasibility and Efficacy Study (EESIS-FR) (Photo: Evasc Neurovascular)
The procedural success of the second generation eCLIPs Bifurcation Remodelling System will be evaluated to determine its feasibility and safety will be measured as of a major stroke or death within 30 days, or major territorial stroke or neurological death within one year. Additional endpoints will be evaluated, and data collected to assess the procedural success and to collect efficacy information on the other eCLIPs products.
“I am pleased to have enrolled the first patient in this important clinical study to help further the clinical understanding of the real-world effectiveness of the second generation eCLIPs Aneurysm Treatment System. We have seen an enormous improvement in the second generation eCLIPs delivery system: stability and placement within eight minutes is a game-changer in the neurointerventional practise,” said Dr. Raphael Blanc, Principal Investigator of the study and Consultant Interventional Neuroradiologist and Deputy Head of the Department of Interventional Neuroradiology at Rothschild Foundation Hospital, Paris, France.
“Thanks to our French partners, we have achieved this significant milestone after many years of hard work,” said Dr. Donald Ricci, President and Chief Executive Officer of Evasc Neurovascular.
About the eCLIPs Aneurysm Treatment System
eCLIPs is a non-tubular endovascular device currently targeted for use in challenging wide-neck bifurcations, using technology designed to treat 95% of cerebral aneurysm cases. The unique eCLIPs design provides not only coil retention, but also flow diversion at the neck. eCLIPs avoids dangerous entry into the dynamic, fragile environment of the aneurysm sac while leaving side branches unencumbered and providing a platform for endothelial growth across the bifurcation neck.
About Evasc
Evasc Neurovascular is a privately held medical device company focused on the development of disruptive endovascular treatments for cerebral aneurysms. Evasc Neurovascular is headquartered in Vancouver, Canada. For additional information, please visit evasc.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220111006183/en/
Contact information
Scott Wilson, +1 (604) 742-3811, wilson@evasc.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Blue Cloud Ventures Announces Final Close of Blue Cloud Ventures V2.6.2026 17:35:00 EEST | Press release
Blue Cloud Ventures (BCV), a venture growth firm focused on investing in enterprise software companies, announced the final close of its fifth fund, Blue Cloud Ventures V (BCV V). This milestone reinforces the firm’s continued mission to back category-defining companies that are poised to thrive in the age of AI. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260602186634/en/ At the core of BCV’s strategy is building deep conviction in and backing companies that possess the potential to define or reshape entire industries. With BCV V, the firm is doubling down on its AI-first investment thesis, aiming to back and support visionary teams on their long-term growth journey as they build the systems that will serve as the backbone of the modern enterprise. Blue Cloud typically invests between $10 and $30 million as a lead, co-lead, or co-investor. Beyond support with strategy, recruiting, and customer introductions, the firm pro
IQM, a Global Leader in Quantum Computing, and Real Asset Acquisition Corp. Announce Upsized USD 146 million PIPE with New Commitment from Ilmarinen2.6.2026 17:17:00 EEST | Press release
IQM Finland Oy, a global leader in full-stack superconducting quantum computers (“IQM”, “IQM Quantum Computers” or the “Company”) and Real Asset Acquisition Corp. (Nasdaq: RAAQ), a special purpose acquisition company (“RAAQ”), today announced an additional PIPE commitment from Ilmarinen in connection with the previously announced business combination between IQM and RAAQ. Ilmarinen’s new commitment comes alongside commitments from other leading institutional investors in the previously announced USD 134 million PIPE. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260602993879/en/ IQM quantum computer The incremental PIPE provides additional funding on top of the previously announced USD 134 million in PIPE financing proceeds to be used to accelerate IQM’s technology and commercial development towards fault-tolerant quantum computing, further advancing its position as a leading provider of quantum computers. Headquartered in
Laserfiche Launches on AWS Marketplace, Bringing Intelligent Content Management to the Enterprise2.6.2026 17:00:00 EEST | Press release
Laserfiche — the leading SaaS provider of intelligent content management — has partnered with AWS to make Laserfiche available through AWS Marketplace. This collaboration enables AWS customers to seamlessly procure Laserfiche’s document management platform to manage content, automate workflows and implement agentic AI capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260602537198/en/ Laserfiche intelligent content management is now available to procure directly through AWS Marketplace. “We’re excited about this evolution of our long-standing partnership with AWS,” said Thomas Phelps, Laserfiche senior vice president of corporate strategy and CIO. “AWS Marketplace provides a near-frictionless experience for Laserfiche direct customers who want to accept negotiated private offers, manage billing and payment history, and apply eligible purchases toward their AWS Enterprise Discount Program (EDP) commitments — all thr
Experian Brings Trusted Agentic AI to Financial Services With the Launch of Agent Operating System™2.6.2026 16:05:00 EEST | Press release
Experian today announces the launch of the Agent Operating System™, a trusted agentic AI layer within the Experian Ascend Platform, unveiled at Money20/20 Europe. The Experian Agent Operating System is designed to help financial services organisations move successfully beyond AI experimentation and safely scale agentic AI to transform decision-making, customer experiences, and day-to-day operations. It enables AI agents from Experian, clients and partners to work together through a common trust, semantic and orchestration layer, supported by clear controls, auditability and human oversight. The launch comes as financial services firms accelerate investment in AI but continue to face major barriers to scaling adoption. New Experian research* shows that nearly half of global organisations (48%), say integrating data into AI workflows remains difficult, while a third cite poor data lineage and a further third say data is siloed across teams and systems. At the same time, consumers are inc
High Q Technologies and Creative Biostructure Announce Strategic Partnership Expanding Global Access to Quantum-Enabled EPR Spectroscopy2.6.2026 16:00:00 EEST | Press release
High Q Technologies, a developer of quantum-enabled electron paramagnetic resonance (EPR) spectroscopy systems, and Creative Biostructure, a structural biology Contract Research Organization, today announced a strategic partnership to support broader adoption of EPR spectroscopy for studying protein dynamics in pharmaceutical and biotechnology research. EPR spectroscopy is increasingly relevant as drug discovery turns toward disordered, flexible, and disease‑relevant protein systems that cannot be fully understood through static structural methods alone. However, broad adoption of EPR has historically been limited by instrument and workflow complexity, and the need for dedicated technical expertise in experimental design and data interpretation. Leveraging quantum sensor technology, FATHOM® EPR has overcome these challenges. By providing unique measurements of long‑range distances, FATHOM® EPR enables researchers to probe conformational ensembles and molecular motion implicated in toda
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom